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Abstract  
Glucose Transporter 4 (GLUT4) is sequestered inside muscle and fat, then released 
by vesicle traffic to the cell surface in response to post-prandial insulin for blood 
glucose clearance. Here we map the biogenesis of this GLUT4 traffic pathway in 
humans, which involves clathrin isoform CHC22. We observe that GLUT4 transits 
through the early secretory pathway more slowly than the constitutively-secreted 
GLUT1 transporter and localize CHC22 to the endoplasmic-reticulum-to-Golgi-
intermediate compartment (ERGIC). CHC22 functions in transport from the ERGIC, 
as demonstrated by an essential role in forming the replication vacuole of Legionella 
pneumophila bacteria, which requires ERGIC-derived membrane. CHC22 complexes 
with ERGIC tether p115, GLUT4 and sortilin and down-regulation of either p115 or 
CHC22, but not GM130 or sortilin abrogate insulin-responsive GLUT4 release. This 
indicates CHC22 traffic initiates human GLUT4 sequestration from the ERGIC, and 
defines a role for CHC22 in addition to retrograde sorting of GLUT4 after endocytic 
recapture, enhancing pathways for GLUT4 sequestration in humans relative to mice, 
which lack CHC22. 
 
Summary: 
Blood glucose clearance relies on insulin-stimulated exocytosis of glucose 
transporter 4 (GLUT4) from sites of intracellular sequestration in muscle and fat. This 
work demonstrates that in humans, CHC22 clathrin controls GLUT4 traffic from the 
Endoplasmic Reticulum-to-Golgi Intermediate Compartment to the sites of 
intracellular sequestration during GLUT4 pathway biogenesis. 
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Glucose transporter 4 (GLUT4) mediates post-prandial blood glucose clearance into 
muscle and adipose tissues following insulin-stimulated translocation to the cell 
surface from sites of intracellular sequestration, known collectively as the GLUT4 
storage compartment (GSC) (Bogan, 2012; Leto and Saltiel, 2012). Deregulation of 
GLUT4 vesicle release occurs during insulin resistance and contributes to 
pathogenesis of type 2 diabetes (T2D) (Bogan, 2012). In rodent models, endocytic 
pathways have been identified as essential routes for recycling of GLUT4 to reform 
insulin-responsive vesicles after insulin-mediated release (Antonescu et al., 2008; 
Bryant et al., 2002; Fazakerley et al., 2009; Jaldin-Fincati et al., 2017; Kandror and 
Pilch, 2011). Endosomal sorting and retrograde transport through the trans-Golgi 
network is involved in this process, generating the GSC (Shewan et al., 2003), which 
is a mixture of tubules and vesicles in which GLUT4 is sequestered in the absence of 
insulin. The trafficking routes by which newly synthesized GLUT4 accesses the GSC 
and participates in its formation are less well defined. In human myocytes and 
adipocytes, GSC formation involves the non-canonical isoform of clathrin, CHC22, 
which is missing from rodents due to loss of the encoding gene (Wakeham et al., 
2005). Here we define a role for CHC22 clathrin in the biosynthetic trafficking 
pathway delivering GLUT4 to the GSC in humans. 
 
The non-canonical clathrin isoform CHC22 is encoded on human chromosome 22 
and has 85% sequence identity with the canonical CHC17 clathrin isoform 
(Wakeham et al., 2005). CHC17 performs receptor-mediated endocytosis at the 
plasma membrane and protein sorting at the trans-Golgi network in all eukaryotic 
cells and tissues (Brodsky, 2012). CHC22 has been implicated in distinct tissue-
specific membrane traffic pathways consistent with its different biochemical 
properties and restricted tissue expression. While both CHC22 and CHC17 homo-
trimerize into triskelia that assemble to form latticed vesicle coats, the CHC22 coat is 
more stable and, within cells, the two clathrins form separate vesicles (Dannhauser 
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et al., 2017). CHC22 does not bind the clathrin light chain subunits associated with 
CHC17 or the endocytic AP2 adaptor that recruits CHC17 to the plasma membrane, 
while CHC22 interacts preferentially with the GGA2 adaptor compared to CHC17 
(Dannhauser et al., 2017; Liu et al., 2001; Vassilopoulos et al., 2009). In agreement 
with its adaptor specificity, several analyses have now confirmed that CHC22 does 
not support receptor-mediated endocytosis at the plasma membrane (Dannhauser et 
al., 2017), though earlier studies suggested that it might replace CHC17 function 
upon over-expression (Hood and Royle, 2009).  
 
In humans, CHC22 is expressed most highly in muscle, reaching about 10% of 
CHC17 levels, and has variable but lower expression in other tissues (Esk et al., 
2010). In both human myocytes and adipocytes, CHC22 is needed for formation of 
the GSC, a membrane traffic pathway that these cell types uniquely share 
(Vassilopoulos et al., 2009). We previously observed that CHC22 is required for a 
retrograde transport pathway from endosomes (Esk et al., 2010), a step that CHC17 
can also perform (Johannes and Popoff, 2008) and which has been shown to be 
important in murine GSC formation (Jaldin-Fincati et al., 2017). However, when 
CHC22 is depleted from human myocytes, CHC17 does not compensate for CHC22 
loss and cells are unable to form an insulin-responsive GSC, suggesting that CHC22 
mediates an additional pathway in human GSC formation (Vassilopoulos et al., 
2009). CHC22 is also transiently expressed in the developing human brain (Nahorski 
et al., 2015) and has been implicated in protein targeting to dense core secretory 
granules, another pathway that involves sequestration of cargo away from standard 
endocytic and secretory pathways (Nahorski et al., 2018). 
 
In the adipocytes and myocytes of insulin resistant type-2 diabetic patients, GLUT4 
accumulates intracellularly (Garvey et al., 1998; Maianu et al., 2001), in a region 
where CHC22 also accumulates (Vassilopoulos et al., 2009). Transgenic expression 
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of CHC22 in murine muscle caused similar accumulation of GLUT4 with CHC22 
along with two other proteins involved in intracellular GLUT4 sorting, IRAP and 
VAMP2, and aged CHC22-transgenic animals developed hyperglycemia. These 
observations not only highlight fundamental differences in GLUT4 intracellular 
trafficking to the GSC between human and mice, but also link abnormal CHC22 
intracellular localization and function to defects in GLUT4 trafficking during insulin 
resistance. Therefore, mapping the CHC22-mediated GLUT4 trafficking pathways 
leading to the biogenesis of the GSC in humans is relevant to pathophysiology 
leading to type 2 diabetes. 8QGHUVWDQGLQJ&+&¶VUROHLQ*/87WUDIILFVKRXOGDOVR
shed light on its role during the development of pain-sensing neurons, which was 
found to be defective in children homozygous for a rare familial mutation in the 
CHC22-encoding gene, who unfortunately did not survive to an age where their 
glucose metabolism could be studied (Nahorski et al., 2015). 
 
In the present study, we identify a specialized pathway that CHC22 mediates during 
biogenesis of the human GSC by analyzing CHC22 function and distribution in 
several human cell models. We observed that CHC22 localizes to the early secretory 
pathway where GLUT4 is delayed during its biogenesis relative to the constitutively-
secreted GLUT1 transporter. In particular, CHC22 co-localizes and complexes with 
p115, a resident of the ER-to-Golgi Intermediate Compartment (ERGIC). Consistent 
with its function in membrane export from the ERGIC, CHC22 was necessary for 
forming the replication vacuole of the bacterium Legionella pneumophila, which co-
opts membrane from the ERGIC to avoid the degradative environment of the 
endocytic pathway. The bacterial compartment also acquired IRAP, sortilin and 
GGA2, other essential components of the GLUT4 pathway. We further found that 
CHC22-dependent GLUT4 transport to the human GSC relies on p115 but not 
GM130, indicating that this pathway depends on membrane traffic from the ERGIC in 
an unconventional secretory route for intracellular sequestration. 
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Results 
HeLa-GLUT4 cells have an insulin-responsive GLUT4 trafficking pathway that 
requires CHC22. 
To study the role of CHC22 in formation of the human GSC, we established a cellular 
model in which GLUT4 translocation can be easily detected. This was necessitated 
by the limited experimental capacity of available human muscle and adipocyte cell 
lines and the lack of reagents to detect endogenous GLUT4 at the cell surface. We 
generated a stable HeLa cell line (HeLa-GLUT4) expressing human GLUT4 
containing a haemagglutinin (HA) tag in the first exofacial loop and a GFP tag at the 
intracellular carboxyl terminus, a construct that has been extensively characterized 
and validated for the study of intracellular GLUT4 trafficking in rodent cells (Dawson 
et al., 2001; Dobson et al., 1996). HeLa cells were chosen because they have levels 
of CHC22 comparable to those in human muscle cells (Esk et al., 2010) and they 
also express sortilin, another protein important for GLUT4 traffic to an insulin-
responsive compartment (Huang et al., 2013; Shi and Kandror, 2005; Shi and 
Kandror, 2007).  
 
GLUT4 was sequestered intracellularly in HeLa-GLUT4 cells in the absence of 
insulin (basal), localizing to peripheral vesicles (arrowheads) and a perinuclear depot 
(arrows), as observed for insulin-releasable GLUT4 vesicles and the tubulo-vesicular 
GSC of murine cells (Bryant et al., 2002; Shewan et al., 2003) (Fig. 1 A). Upon 
insulin treatment (15 min), GLUT4 was detected at the cell surface using a 
monoclonal antibody to the haemagglutinin (HA) tag (anti-HA) (Fig. 1 A). GLUT4 
translocation was quantified using a fluorescence-activated cell sorter (FACS) to 
measure the mean fluorescence intensity (MFI) of surface GLUT4 relative to the MFI 
of total cellular GLUT4 (GFP signal) (Fig. 1 B). Additionally, treatment of HeLa-
GLUT4 cells with insulin induced phosphorylation of AKT and its substrate AS160, 
two modifications required for insulin-stimulated GLUT4 translocation (Bogan, 2012) 
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(Fig. 1 B). Intracellular sequestration and insulin responsiveness of GLUT4 was 
observed to be specific by comparison to endogenous Class I molecules of the Major 
Histocompatibility Complex (MHCI), which were constitutively expressed at the 
plasma membrane of HeLa-GLUT4 cells, clearly segregated from GLUT4 under 
basal conditions (Fig. 1 C), and unchanged by insulin treatment. Upon insulin 
treatment, GLUT4 co-localized with MHCI at the cell surface and this was prevented 
by treatment of HeLa-GLUT4 cells with siRNA targeting CHC22 (Fig. 1 C and D). 
Down-regulation of CHC22 did not affect the distribution of MHCI in either basal or 
insulin-stimulated conditions (Fig. 1 C). Thus formation of the insulin-responsive 
GLUT4 pathway in HeLa-GLUT4 cells depends on CHC22. 
 
In rodent cells, GLUT4 released by insulin to the plasma membrane can return by 
endocytosis and retrograde transport to a syntaxin 6 (STX-6)±positive GSC within 30 
minutes (Perera et al., 2003). Replicating this pulse-chase experiment in the HeLa-
GLUT4 model, we labeled surface GLUT4 with anti-HA antibody following insulin 
stimulation and tracked internalized GLUT4 to a perinuclear compartment 
overlapping with STX-6, with similar kinetics to those observed in rodent cells (Fig. 1 
E and F). Using structured-illumination microscopy (SIM), we observed that, under 
basal conditions, the perinuclear GLUT4 depot in HeLa-GLUT4 cells partially co-
localized with STX-6 (arrowheads, Fig. 1 G), which is considered a marker of the 
GSC in rodent cells (3T3-L1 mouse adipocytes and L6 rat myotubes) (Foley and Klip, 
2014; Shewan et al., 2003). The GSC in HeLa-GLUT4 cells shared properties of the 
GSC in human myoblasts, in that siRNA-mediated depletion of CHC22 induced 
dispersal of GLUT4 from the perinuclear region (Fig. 1 H) and inhibited insulin-
stimulated GLUT4 translocation (Fig. 1 D)(Esk et al., 2010; Vassilopoulos et al., 
2009). Taken together, our results show that HeLa cells stably expressing HA-
GLUT4-GFP form an intracellular GSC, respond to insulin stimulation by rapid 
GLUT4 translocation to the plasma membrane, and recycle GLUT4 back to the GSC. 
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Furthermore, CHC22 expression is required for establishing this GLUT4 trafficking 
pathway. Thus, the model recapitulates features of the GLUT4 pathway observed for 
both mouse and human cells and, while the pathway may not have every regulator of 
GLUT4 traffic in muscle and adipocytes, it can serve to identify players and routes 
involved in GLUT4 trafficking in human cells. We note that during the course of this 
work, other laboratories developed and validated similar models of insulin-dependent 
GLUT4 translocation in HeLa cells (Haga et al., 2011; Trefely et al., 2015). 
 
Newly synthesized GLUT4 co-localizes with CHC22 and is delayed in the early 
secretory pathway relative to constitutively expressed GLUT1. 
Formation of the GSC in rodent cells relies on the biosynthetic pathway feeding the 
GSC with newly synthesized GLUT4 (Watson et al., 2004) and recycling pathways 
that replenish it after insulin-mediated GLUT4 exocytosis (Antonescu et al., 2008; 
Bryant et al., 2002; Fazakerley et al., 2009; Kandror and Pilch, 2011; Martin et al., 
2006). Our previous studies demonstrated a role for CHC22 in human GSC 
formation (Vassilopoulos et al., 2009) and identified a function for CHC22 in 
retrograde transport from endosomes (Esk et al., 2010), suggesting that CHC22 
could participate in GSC replenishment after GLUT4 translocation. To address 
whether CHC22 is also involved in biogenesis of the GLUT4 pathway from the 
secretory pathway, we first tracked newly synthesized GLUT4 relative to the 
constitutively-expressed GLUT1, (Hresko et al., 1994; Hudson et al., 1992). Their 
biosynthetic pathways were compared by the Retention Using Selective Hooks 
(RUSH) approach (Boncompain et al., 2012) for which each transporter was tagged 
with a streptavidin-binding protein (SBP) as well as GFP or mCherry and an HA tag.  
These fusion proteins, HA-GLUT4-SBP-GFP and HA-GLUT1-SBP-mCherry, were 
co-expressed in HeLa cells also expressing streptavidin fused to an ER-resident 
isoform of the human invariant chain (Ii-hook) (Schutze et al., 1994). The ER-
retained HA-GLUT1-SBP-mCherry and HA-GLUT4-SBP-GFP were then 
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synchronously released for ongoing traffic upon addition of biotin to the cells (Fig. 2 
A, Videos 1 and 2). Following release, both transporters showed initial perinuclear 
localization, but after 25 minutes the GLUT1 and GLUT4 pathways diverged and 
vesicles with GLUT1 were observed trafficking to the cell surface (arrowheads, 26-57 
minutes post-biotin addition), while GLUT4 remained concentrated in a perinuclear 
region. This was consistent with the expected constitutive secretion of GLUT1 and 
sequestration of GLUT4 and further demonstrated the specificity of intracellular 
sequestration of GLUT4 in HeLa cells.  
 
We then analyzed these pathways in more detail by visualizing the traffic of HA-
GLUT4-SBP-GFP or HA-GLUT1-SBP-GFP relative to CHC22 and to markers of the 
secretory pathway at different time points after biotin addition, and co-localization 
was quantified. Within 30 minutes of biotin addition, GLUT1 rapidly exited the ER and 
trafficked through the Golgi apparatus as exemplified by the 40% decrease in overlap 
with the ER resident protein calnexin (CNX) (Fig. 2, B and C; black line) and the 
transient increase in overlap with ERGIC markers (p115 and ERGIC-53, Fig. 2 D-G; 
black lines), the Golgi marker GM130 and the trans-Golgi marker TGN46 (Fig. 2, H-
K; black lines). GLUT1 was detected at the plasma membrane as soon as 30 
minutes post ER release (arrows) and by 60 minutes, GLUT1 was detected in 
endosomal structures (arrowheads), indicating internalization from the plasma 
membrane. In contrast, GLUT4 exit from the ER was slower (Fig. 2, B and C, red 
lines). GLUT4 overlap with ERGIC-53, p115 and GM130 and TGN46 increased at 15 
minutes post release but did not decrease over time (Fig. 2, D-K, red lines).  GLUT4 
co-localization with CHC22 was similar to its residence with secretory pathway 
markers, peaking at 15 minutes but remaining more co-localized with CHC22 than 
GLUT1, which only transiently overlapped with CHC22 (Fig. 2 L). Overall, these 
experiments indicate that the trafficking kinetics of newly synthesized GLUT1 and 
GLUT4 are fundamentally different. Moreover, following ER release, GLUT4, and not 
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GLUT1, was retained in a perinuclear region that overlaps with CHC22, suggesting a 
role for CHC22 in trafficking newly synthesized GLUT4 and that CHC22 might 
interact with secretory pathway compartments. 
 
CHC22 localizes with markers of the ER-to-Golgi Intermediate Compartment. 
To identify potential locations for CHC22 function in transporting newly synthesized 
GLUT4, we analyzed CHC22 overlap with markers of the secretory pathway in HeLa-
GLUT4 cells and in human myotubes formed by differentiation of two different human 
myoblast cell lines (LHCNM2 or hSkMC-AB1190-GLUT4) (Figs. 2 M, S1, 3 and 4). 
The LHCNM2 cells express low levels of endogenous GLUT4 upon differentiation 
(Vassilopoulos et al., 2009) and the hSkMC-AB1190-GLUT4 cells were derived from 
the transformed human myoblast (line AB1190) by transfection and selected for 
permanent expression of HA-GLUT4-GFP. These cells were analyzed to establish 
whether pathways identified in the HeLa-GLUT4 cells are present in human 
myotubes where the GLUT4 pathway naturally operates. Using a commercially 
available polyclonal antibody specific for CHC22 and not reactive with CHC17 (Fig. 
S1 A), we observed significant co-localization of CHC22 with two markers of the 
ERGIC, namely p115 (Alvarez et al., 2001) and ERGIC-53 (Lahtinen et al., 1996) in 
both the HeLa-GLUT4 model and in human myotubes (Figs. 2 M and S1 B and C). 
CHC22 only partially overlapped with Golgi markers GM130 and TGN46 (Figs. 2 M 
and S1 D and E) and no significant co-localization was seen with ER markers 
calreticulin or calnexin in all cell lines (Figs. 2 M and S1 F and G). Given the limited 
spatial resolution of conventional laser scanning confocal microscopy (200 nm), 
these overlap values could be overestimated. We therefore used super-resolution 
Structured Illumination Microscopy (SIM), which improves lateral resolution twofold 
(100 nm). Using SIM, we confirmed the substantial overlap between CHC22 and 
ERGIC markers p115 and ERGIC-53 in HeLa-GLUT4 and in the human skeletal 
muscle cells (Figs. 3 A-D, arrowheads, and S1 I) with most extensive overlap 
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between CHC22 and p115. SIM analysis did not support the apparent overlap 
between CHC22 and Golgi markers obtained by confocal microscopy in either HeLa-
GLUT4 or differentiated human myoblasts. In both cell types, CHC22 was separated 
from cis-Golgi (GM130) and trans-Golgi (TGN46) markers (Figs. 4 A and B and S1 I), 
though localized adjacent to both compartments. Co-staining for p115 and STX-6 
showed alignment of compartments with these markers in both cell types but little 
overlap (Fig. 4 C), suggesting that ERGIC and CHC22 compartments are closely 
associated with but not coincident with sites of GLUT4 retrograde transport. GLUT4 
was widely distributed in the cells analyzed by SIM without preferential co-
localization with any particular marker analyzed.   
 
To further define the relationship between CHC22, ERGIC markers and the 
retrograde transport of GLUT4 internalized after insulin-mediated release, HeLa-
GLUT4 cells were treated with insulin and GLUT4 internalization was tracked by 
uptake of anti-HA antibody. By confocal microscopy, GLUT4 showed time-dependent 
co-localization with CHC22 and ERGIC-53 (Fig. S2) after 10 and 30 minutes of re-
uptake, indicating that recaptured GLUT4 accumulates in close proximity to CHC22 
and the ERGIC. When HeLa-GLUT4 or the hSkMC-AB1190-GLUT4 human 
myotubes were treated with Brefeldin A (BFA), CHC22 co-distributed with the ERGIC 
markers p115, ERGIC-53 and Rab1 and segregated away from the perinuclear 
GLUT4 (Fig. S3). This is consistent with our previous observations that BFA does not 
cause CHC22 to dissociate from intracellular membranes (Liu et al., 2001) and 
supports association of CHC22 with ERGIC membranes. We also observed that BFA 
treatment did not affect GLUT4 release to the plasma membrane in response to 
insulin and that GLUT4 was less localized with CHC22 or ERGIC markers upon 
insulin stimulation, in the presence or absence of BFA (Fig. S3 C-F). This supports 
observations from others showing that GSC formation is not affected by BFA (Martin 
et al., 2000). Together, these data suggest that CHC22-mediated trafficking leads to 
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the GSC, and could be involved in initial GSC formation from the secretory pathway 
by mediating GLUT4 traffic emerging from the ERGIC in addition to its previously 
defined role in retrograde transport from endosomes to the GSC (Esk et al., 2010). 
Furthermore, these results highlight the close proximity of the ERGIC to the 
compartment where GLUT4 accumulates after endocytic recapture. 
 
CHC22 participates in membrane trafficking from the ERGIC. 
To establish whether CHC22 has functional activity at the ERGIC, we took 
advantage of Legionella pneumophila (L.p.), a facultative intracellular pathogen that 
DYRLGV WKHKRVW¶VHQGR-lysosomal compartment and specifically hijacks membranes 
from the early secretory pathway to create an ER/ERGIC-like, L.p.-containing 
vacuole (LCV) for replication (Kagan and Roy, 2002). Upon infection, L.p. secretes 
~300 effector proteins, through a type IV secretion system, some of which enable 
recruitment of ER / ERGIC proteins calnexin, Sec22b, Rab1, ERGIC-53 and Arf1 to 
the LCV (Derre and Isberg, 2004; Kagan and Roy, 2002; Kagan et al., 2004), which 
are needed for its replication. The mature LCV retains ER-like properties, including 
the lumenal proteins calnexin, BiP and calreticulin and does not acquire Golgi 
markers (Derre and Isberg, 2004; Kagan and Roy, 2002; Kagan et al., 2004; Treacy-
Abarca and Mukherjee, 2015). Given that the LCV is derived from the ER, and that 
CHC22 localizes to a compartment emerging from the ER, we tested whether 
CHC22 associates with membranes involved in LCV formation. A549 human lung 
adenocarcinoma cells were transiently transfected to express GFP-tagged CHC22 or 
GFP-tagged CHC17, then infected with L.p.. CHC22, but not CHC17, was associated 
with membrane surrounding the LCV (Fig. 5 A and B). Similar LCV co-localization 
with CHC22 was observed in untransfected cells infected with L.p. and immuno-
stained for endogenous CHC22 or CHC17 (Fig. 5 C). CHC22 did not localize with the 
isogenic avirulent L.p. mutant ǻGRW$ which still enters cells but lacks a functional 
secretion system and cannot secrete effectors to create an ER-like vacuole (Fig. 5 A 
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and B). To further address whether CHC22 is involved in transfer of membrane to the 
LCV, we treated A549 cells with siRNA targeting CHC22 prior to infection. The 
resulting CHC22 down-regulation significantly compromised recruitment of Sec22b to 
the bacterial vacuole at 1 hour post-infection (Fig. S4 A and B), suggesting defective 
vacuole maturation. This was confirmed by assessing bacterial replication eight 
hours after infection with WT or ǻGRW$ L.p. strains following CHC22 or CHC17 
depletion. CHC22 depletion reduced the proportion of vacuoles containing >4 L.p. by 
more than 9-fold, while CHC17 depletion reduced vacuoles with >4 L.p. by only 2-
fold (Fig. 5 D), indicating that CHC22 is required to form a replicative vacuole and a 
possible role for CHC17 during bacterial uptake. The latter conclusion is supported 
by the observation that after CHC22 down-regulation, vacuoles with 1 L.p., indicating 
bacterial entry, were observed, but vacuoles with 1 L.p. were less frequent in cells 
depleted for CHC17 infected with an equivalent number of bacteria. Infection of cells 
transfected with siRNA targeting CHC22 with an equivalent number of avirulent 
ǻGRW$ L.p. showed that these bacteria could also enter cells, with 94% vacuoles 
observed harboring only 1 L.p. (Fig. 5 D). These observations indicate that L.p. 
specifically co-opts CHC22 to acquire membrane derived from the early secretory 
pathway, which is needed for maturation of a replication-competent LCV, and 
suggest that L.p. effectors might interact with CHC22 or its partners. 
 
Since CHC22-mediated membrane traffic contributes to formation of the LCV, we 
addressed whether GLUT4 or other components of the GLUT4 trafficking pathway 
traffic to the LCV. After infection, we observed significant enrichment of sortilin, IRAP 
and GGA2 to the LCV, all known functional partners for intracellular GLUT4 
sequestration (Li and Kandror, 2005; Shi et al., 2008; Shi and Kandror, 2005; Shi and 
Kandror, 2007; Watson et al., 2004) (Fig. 5 E-H). We also observed recruitment of 
Rab1, a host protein that is extensively modified by L.p. during infection (Mukherjee 
et al., 2011) (Figs. 5 E and S4 C). In contrast, the localization of GLUT4 (Figs. 5E 
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and S4 D) or insulin effector Sec16a (Bruno et al., 2016) (Fig. S4 E and F) to the 
LCV was not statistically significant. We also did not detect p115 on the LCV (Fig. 5 
E and I), confirming previous work from others suggesting that one of the L.p. 
effectors LidA bypasses the need for p115 by binding Rab 1 during host membrane 
recruitment (Derre and Isberg, 2004; Machner and Isberg, 2006). Thus, analysis of 
L.p. infection indicates that CHC22 actively traffics membranes from the early 
secretory pathway to the LCV, and that this pathway also traffics a subset of proteins 
involved in forming the GSC. 
 
CHC22 interacts with p115 and each influences stability of different partners 
for GLUT4 membrane traffic. 
Previous work implicated the vesicle tether p115 in murine GSC formation in 3T3-L1 
adipocytes by showing an interaction between p115 and IRAP and demonstrating 
that expression of the interacting fragment of p115 had a dominant negative effect on 
the GLUT4 insulin response (Hosaka et al., 2005). Given the high degree of co-
localization between CHC22 and p115 in human cells, we addressed the possibility 
that CHC22 and p115 might also associate. Endogenous CHC22 or CHC17 were 
immunoprecipitated from lysates of HeLa-GLUT4 (Fig. 6 A) or human skeletal 
muscle myotubes (Fig. 6 B) using an antibody highly specific for CHC22 and the 
most specific antibody available for CHC17, which has slight cross-reactivity with 
CHC22.  An association between p115 and CHC22 was detected in both cell lysates 
and p115 was not co-immunoprecipitated with CHC17 (Fig. 6 A and B). As previously 
found (Vassilopoulos et al., 2009), GLUT4 co-immunoprecipitated preferentially with 
CHC22 compared to its association with CHC17 in both types of cells. We also 
previously showed that, compared to CHC17, CHC22 preferentially co-
immunoprecipitated with the adaptor GGA2 (Dannhauser et al., 2017; Vassilopoulos 
et al., 2009), a reported interactor of sortilin, which is involved in retrograde transport 
of recaptured GLUT4 in murine adipocytes (Pan et al., 2019; Shi et al., 2008; Shi and 
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Kandror, 2005; Shi and Kandror, 2007). Here we found that, in both HeLa-GLUT4 
cells and human skeletal muscle myotubes, sortilin specifically co-
immunoprecipitated with CHC22 but not CHC17 (Fig. 6 C and D). CHC22 was not 
isolated by the anti-sortilin monoclonal antibody used, suggesting that the relevant 
epitope of sortilin was not accessible when associated with CHC22. Thus CHC22 
complexes with molecules from both the early secretory pathway and the GLUT4 
retrograde transport pathway. 
 
To address the relationship of the CHC22-p115 complex with other components of 
the GLUT4 trafficking pathway, we assessed the effects of CHC22 and p115 
depletion on each other and on GLUT4 traffic participants, compared to CHC17 
depletion in HeLa-GLUT4 cells. In particular, we focused on the fate of IRAP, sortilin 
and GGA2. These proteins were all found associated with the LCV (Fig. 5 E-H) and 
all three have been implicated in rodent GSC formation, as well as found in 
complexes with each other (Li and Kandror, 2005; Shi et al., 2008; Shi and Kandror, 
2005; Shi and Kandror, 2007; Watson et al., 2004). CHC22 depletion destabilized 
GLUT4, sortilin and GGA2 while p115 and IRAP remained unchanged (Fig. 6 E, F 
and I). Conversely, p115 depletion destabilized IRAP (Fig. 6 F and J) but none of the 
other components. None of the GLUT4 trafficking components were destabilized 
upon CHC17 depletion (Fig. 6 E, F and H), which, as previously observed 
(Dannhauser et al., 2017; Esk et al., 2010; Vassilopoulos et al., 2009), stabilized 
CHC22, likely due to increased membrane association as a result of reduced 
competition for shared adaptors such as GGA2 and AP1. Combining these 
observations with the immunoprecipitation results suggests one minimal complex 
between CHC22, GGA2, sortilin and GLUT4 and another minimal complex between 
CHC22, p115, IRAP and GLUT4, with the former playing a role in retrograde GLUT4 
sorting and the latter playing a role in sorting newly synthesized GLUT4.  
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Membrane traffic to the human GSC requires CHC22 and p115, but not GM130. 
To investigate the involvement of the early secretory pathway in sorting GLUT4 
during GSC formation in human cells, we depleted CHC22, p115 or the cis-Golgi 
tether protein GM130 from HeLa-GLUT4 cells using siRNA (Fig. 7 A) and assessed 
the distribution of GLUT4 by confocal microscopy (Fig. 7 B and C). Depletion of p115 
or of CHC22 caused loss of perinuclear GLUT4 and dispersion in the cell periphery, 
with down-regulation of one affecting the distribution of the other (Fig. 7 B). We did 
not detect any impact of GM130 depletion on GLUT4 subcellular distribution, though 
GM130 depletion did partially alter p115 distribution (Fig. 7 C). Since IRAP and 
sortilin were found to associate with p115 and CHC22, we also tested the effects of 
their down-regulation on GLUT4 distribution and observed no obvious effects of 
these treatments (Fig. 7 A, D, E), indicating differences in requirements for IRAP and 
sortilin in targeting GLUT4 in this human model compared to the murine adipocyte 
model.  
 
To determine the functional effects of altering GLUT4 distribution in the HeLa-GLUT4 
cells, we evaluated how depletion of CHC22, p115, GM130, IRAP, and sortilin 
affected insulin-induced GLUT4 translocation, as assessed by FACS analysis (Fig. 8 
A and B). Insulin-stimulated GLUT4 translocation was lost from cells depleted of 
p115 or CHC22 while CHC17 depletion had a partial effect on GLUT4 translocation 
(Fig. 8 A), consistent with previous observations for CHC22 and CHC17 down-
regulation (Vassilopoulos et al., 2009). Corresponding to immunofluorescence 
analyses (Fig. 7 C-E), down-regulation of GM130, IRAP and sortilin (or the 
combination of IRAP and sortilin) did not affect insulin-stimulated GLUT4 
translocation (Fig. 8 A and B). To confirm that GM130 depletion affected export from 
the Golgi, we demonstrated reduction of alkaline phosphatase secretion from the 
siRNA-treated cells (Tokumitsu and Fishman, 1983) (Fig. S5). These translocation 
assays further indicate that CHC22 and p115 are essential for formation of the 
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human GSC and that this process requires membrane traffic from the early secretory 
pathway that bypasses the Golgi.  
 
Discussion 
CHC22 clathrin is required for formation of the insulin-responsive GLUT4 storage 
compartment (GSC) in human muscle and fat (Esk et al., 2010; Vassilopoulos et al., 
2009) and has been implicated in specialized membrane traffic to dense core 
granules in neuronal cells (Nahorski et al., 2018). Both of these roles require 
diversion of intracellular cargo into privileged storage compartments so that the cargo 
is sequestered from degradation. Previous studies indicated a role for CHC22 
clathrin in retrograde transport from endosomes (Esk et al., 2010), where CHC17 has 
been implicated in returning insulin-released GLUT4 to the GSC in murine cells 
(Gillingham et al., 1999; Li and Kandror, 2005). However, depletion of CHC22 from 
human muscle cells abrogates GSC formation even in the presence of CHC17 
(Vassilopoulos et al., 2009), so we suspected a second pathway for CHC22 function 
in GLUT4 transport unique to this isoform of clathrin.  We focused on pathways that 
would be involved in biosynthetic formation of the GSC, as evidence suggests that 
GLUT4 arrives at the GSC prior to its expression on the plasma membrane (Watson 
et al., 2004). Discovering strong co-localization of CHC22 with the ERGIC markers 
p115 and ERGIC-53, we investigated a role for CHC22 in formation of the replication 
vacuole of Legionella pneumophila (L.p.), which acquires membrane from the early 
secretory pathway to evade degradative compartments (Derre and Isberg, 2004; 
Kagan and Roy, 2002).  We found that CHC22 was required for bacterial replication 
and formation of the L.p.-containing vacuole (LCV), and that components of the 
GLUT4 trafficking pathway localized to the LCV, though the presence of GLUT4 itself 
was variable. A difference between LCV and GSC formation is a requirement for 
cellular p115. We showed that p115 was needed for human GSC formation, and it 
has previously been implicated in murine GSC formation (Hosaka et al., 2005), but 
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L.p. bacteria have an effector protein that replaces p115 (Machner and Isberg, 2006). 
Our studies therefore indicate that human GSC formation requires CHC22-
dependent membrane derived from the ERGIC, in a pathway similar to that co-opted 
by L.p. bacteria. 
 
Tracking newly synthesized GLUT4, using the RUSH system, we observed that 
GLUT4 resides for a longer period of time with markers of the early secretory 
pathway compared to the behavior of constitutively secreted GLUT1 after their 
release from the ER. We also found that while formation of the human GSC was 
sensitive to depletion of p115 and CHC22, GSC formation was not affected by 
depletion of GM130. These data suggest that the CHC22-mediated pathway 
transports GLUT4 to a site where it can be sequestered for generation of insulin-
responsive vesicles and further suggests a Golgi bypass occurs in this step of GSC 
biogenesis. The reported slow maturation of carbohydrate side chains on GLUT4 
compared to GLUT1 is consistent with the proposed Golgi bypass (Hresko et al., 
1994; Hudson et al., 1992). Delayed modification of GLUT4 carbohydrate could 
result from pre-Golgi diversion of most newly synthesized GLUT4 from the ERGIC, 
followed by a process of carbohydrate maturation that depends on GLUT4 secretion 
and recapture through a retrograde pathway (Shewan et al., 2003) where low-level 
carbohydrate modification can occur by Golgi enzymes being recycled to their home 
compartments (Fisher and Ungar, 2016). In our studies, we localized ERGIC 
membrane with CHC22 and/or p115 in close proximity to, but not completely 
overlapping with, compartments containing GLUT4 internalized after insulin-mediated 
release and intracellular compartments marked by STX-6, a TGN marker that co-
localizes with internalized GLUT4. This is consistent with a biogenesis pathway 
connecting GLUT4 emerging from the ERGIC with the pool of GLUT4 sequestered 
after internalization for reformation of insulin-responsive vesicles. It is also consistent 
with ER/ERGIC-associated proteins being involved in insulin-mediated GLUT4 
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release, such as the TUG vesicle tethering protein (Orme and Bogan, 2012) and the 
ER-exit site protein Sec16A (Bruno et al., 2016). Proximity of GLUT4 emerging from 
early secretory compartments with compartments generating insulin-responsive 
GLUT4 vesicles could explain sharing of effector molecules and would also explain 
the general insensitivity of the GSC to BFA disruption, as shown here and earlier 
(Martin et al., 2000). 
 
Our demonstration that CHC22 functions in transport from the early secretory 
pathway defines a membrane traffic step in which the canonical CHC17 clathrin is 
not involved (Brodsky, 2012). We show here that CHC22 co-immunoprecipitates with 
p115 and sortilin and that CHC17 does not, further demonstrating that the two 
clathrins form distinct complexes (Vassilopoulos et al., 2009), localize to distinct 
cellular regions (Liu et al., 2001) and form distinct coated vesicles (Dannhauser et 
al., 2017). It was previously shown that p115 interacts with IRAP (Hosaka et al., 
2005), a protein that binds GLUT4 and is co-sequestered in GLUT4 vesicles (Shi et 
al., 2008) and that expression of a p115 fragment prevents GSC formation in murine 
cells (Hosaka et al., 2005). We show here that p115 down-regulation reduces the 
stability of IRAP. Thus, we propose that CHC22-p115-IRAP interaction occurs in the 
human ERGIC and triggers the coalescence of a protein domain that captures 
GLUT4 for sorting to the GSC (Fig. 8C). Taking into account our earlier 
demonstration of a role for CHC22 in retrograde transport from endosomes and its 
preferential interaction with the endosome-TGN adaptor GGA2 (Dannhauser et al., 
2017; Vassilopoulos et al., 2009) as well as the interaction with sortilin shown here, 
we propose that a second complex involving CHC22, sortilin and GGA2 sorts 
internalized GLUT4 to the compartment where insulin-responsive vesicles are 
generated (Fig. 8C). Thus, CHC22 clathrin can play a role in sorting both newly 
synthesized and internalized GLUT4 to the human GSC.  
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GLUT4 membrane traffic has primarily been studied using murine adipocyte and rat 
myoblast cell lines, which do not express CHC22 as a result of gene loss in the 
rodent lineage (Fumagalli et al., 2019; Wakeham et al., 2005). Such studies have 
established that the major pathway for targeting GLUT4 to the GSC in rodent cells 
relies on retrograde transport of GLUT4, via endosomal-TGN sorting, after its release 
to the cell surface from the GSC and uptake by CHC17 (Bryant et al., 2002; Jaldin-
Fincati et al., 2017). Our studies here (Fig. 1) support the existence of this retrograde 
pathway in human cells. It is also reported that in rodent cells GLUT4 reaches the 
GSC prior to its insulin-stimulated release to the cell surface (Lamb et al., 2010; 
Watson et al., 2004), and in rodent cells there is involvement of p115 in GSC 
formation (Hosaka et al., 2005). Thus, both direct targeting and endocytic recapture 
pathways seem to be involved in GSC formation in humans and rodents. In humans 
the CHC22 coat mediates both pathways, but rodents only have the CHC17 coat to 
mediate retrograde sorting. So rodents must rely simply on coalescence of relevant 
cargo (GLUT4, IRAP and p115) in the ERGIC to segregate them from other proteins 
constitutively leaving the secretory pathway and this is likely less efficient, perhaps 
with some GLUT4 directly accessing the cell surface for rapid re-uptake in the 
absence of insulin (Martin et al., 2000). In this case, population of the rodent GSC 
with GLUT4 is mainly a result of the retrograde recycling pathway, in which sortilin 
and IRAP have been shown to participate (Jordens et al., 2010; Pan et al., 2019; Pan 
et al., 2017; Sadler et al., 2019). In the case of human cells, CHC22 can actively 
capture GLUT4 and partners for diversion to the GSC, providing a more robust route 
to GSC formation following biosynthesis, with the GSC also replenished with GLUT4 
by the endocytic-retrograde recycling pathway. The fact that humans have a very 
stable coat contributing to each sorting step (CHC22 is more stable than CHC17) 
(Dannhauser et al., 2017; Liu et al., 2001), may explain why neither sortilin nor IRAP 
knockdown affected GSC formation in our human model, even if they are functionally 
important cargo for GLUT4 sorting (Fig. 7E and F). The species difference in 
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membrane dynamics of GLUT4 traffic has the effect that human cells cannot form a 
GSC with only CHC17 and require both CHC22 pathways. However, the presence of 
CHC22 enhancing biosynthetic GSC formation may have the consequence that 
humans are able to sequester intracellular GLUT4 more efficiently than species 
without CHC22, a trait that may contribute to a tendency to insulin resistance.  
 
Identification of this sorting pathway for GLUT4 from the ERGIC to the GSC adds to 
the variety of sorting pathways that are known to emerge from the ERGIC, sustaining 
both conventional (ER-to-Golgi) (Kondylis and Rabouille, 2003; Sohda et al., 2007) 
and unconventional (Golgi bypass) pathways for autophagy (Ge et al., 2013; Ge and 
Schekman, 2014) or cargo exocytosis (Piao et al., 2017). In humans and even in 
CHC22 transgenic mice, CHC22 expression parallels that of GLUT4, with its highest 
expression in GLUT4-expressing tissues (Hoshino et al., 2013). However, unlike the 
tight regulation of GLUT4 expression, CHC22 is expressed at low levels in additional 
cell types (Nahorski et al., 2015). Thus, the CHC22 sorting pathway emerging from 
the ERGIC that we define here and CHC22-mediated retrograde sorting may also 
operate in tissues that do not express GLUT4 to target yet-unidentified cargo to 
specialized organelles, avoiding the conventional secretory or endocytic pathways. 
 
Materials and Methods 
Plasmids 
The HA-GLUT4-GFP construct was a gift from Dr Tim McGraw (Lampson et al., 
2000). The plasmid encoding human GLUT1 was from OriGene. The haemagglutinin 
(HA-)tag sequence atcgattatccttatgatgttcctgattatgctgag was inserted at base pair 201 
(between amino acids 67 and 68 of the exofacial loop of GLUT1) using the Q5 site-
directed mutagenesis kit from New England Biolabs (NEB, USA). HA-GLUT4 and 
HA-GLUT1 were extracted using AcsI and EcoRI restriction enzymes and Cutsmart 
buffer from NEB and the agarose gel extraction kit from Qiagen. The inserts were 
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then ligated into the RUSH plasmid containing the ER Ii-hook fused to streptavidin, to 
generate the HA-GLUT4-SBP-GFP construct (Boncompain et al., 2012; Boncompain 
and Perez, 2013). In order to generate the HA-GLUT1-SBP-mCherry plasmid, we 
swapped the GFP tag in the HA-GLUT1-SBP-GFP for mCherry, using the SbfI and 
FseI restriction enzymes. The generation of plasmids encoding GFP-tagged CHC22 
and CHC17 has been described elsewhere (Esk et al., 2010). 
 
Cell culture 
All cell lines were maintained at 37°C in a 5% CO 2 atmosphere. The HeLa cell line 
stably expressing GLUT4 (HeLa-GLUT4) was generated by transfection of HeLa 
cells with the plasmid encoding HA-GLUT4-GFP (Dawson et al., 2001; Lampson et 
al., 2000; Quon et al., 1994). Transfectants were selected in growth medium 
supplemented with 700 ȣg/mL G418 then maintained in growth medium with 500 ȣ
g/mL G418. The human skeletal muscle cell line LHCNM2 was described elsewhere 
(Esk et al., 2010; Vassilopoulos et al., 2009; Zhu et al., 2007). A549 human lung 
carcinoma cells were obtained from the ATCC. HeLa and A549 cells were grown in 
Dulbecco̓s Modified Eagle Medium high glucose supplemented with 10% FBS 
(Gibco), 50 U/mL penicillin, 50 ȣg/mL streptomycin (Gibco), 10 mM Hepes (Gibco). 
LHCNM2 cells were grown in proliferation medium: DMEM MegaCell (Sigma) 
supplemented with 5% FBS (Gibco), 2 mM L-Glutamine (Sigma), 1% non-essential 
amino acids (Sigma), 0.05 mM ș-mercaptoethanol (Gibco) and 5 ng/mL FGF 
(Thermo Fisher Scientific). When full confluency was reached, cells were switched to 
differentiation medium: DMEM (Sigma) supplemented with 2 mM L-Glutamine 
(Sigma), 50 U/mL penicillin and 50 ȣ g/mL streptomycin (Gibco). The human 
myoblast cell line AB1190 was immortalized using the platform for immortalization of 
human cells from the Institut de Myologie (Paris). These cells were grown in 
complete Skeletal Muscle Cell Growth Medium (Promocell) supplemented with 
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serum to reach 20% final concentration (V/V). These cells were transfected to 
express HA-GLUT4-GFP and permanently transfected myoblasts (hSkMC-AB1190-
GLUT4) were selected for their ability to differentiate into myotubes. Differentiation of 
confluent hSkMC-AB1190 myoblasts and hSkMC-AB1190-GLUT4 myoblasts was 
induced by incubating the cells in differentiation medium for 6 to 7 days: DMEM 
(Gibco), Gentamycin 50 ȣg/ml (Gibco) + insulin 10 ȣg/ml (Sigma). All cell lines 
used were tested negative for mycoplasma infection. 
 
Small RNA interference 
Targeting siRNA was produced (Qiagen) to interact with DNA sequences 
AAGCAATGAGCTGTTTGAAGA for CHC17 (Esk et al., 2010), 
TCGGGCAAATGTGCCAAGCAA and AACTGGGAGGATCTAGTTAAA for CHC22 
(1:1 mixture of siRNAs were used)(Vassilopoulos et al., 2009) and 
AAGACCGGCAATTGTAGTACT for p115 (Puthenveedu and Linstedt, 2004). 
Targeting siRNA against sortilin and IRAP were purchased from OriGene 
(SR304211, SR302711, respectively). Non-targeting control siRNA was the Allstars 
Negative Control siRNA (Qiagen). siRNA targeting GM130 and scrambled negative 
control siRNA were purchased from OriGene (SR301869). For siRNA treatments, 
cells were seeded (10,000 cells/cm2) in 6- or 24-well plates in culture medium. The 
next day, the cells were transfected with siRNAs complexed with JetPrime 
(PolyPlus). For targeting CHC17, p115 and GM130, 20 nM of siRNA was used per 
treatment. For targeting CHC22, 20 nM of siRNA was used per treatment, except for 
Western blot experiments in Figure 6 where 40 nM of siRNA were used. For IRAP 
and sortilin knockdowns, 30 and 40 nM of siRNA were transfected, respectively. Six 
hours after siRNA transfection, cells were returned to normal growth conditions and 
then harvested for analysis or fixed for imaging 72 h later. Depletion was assessed 
by immunoblotting. 
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Transfection 
For transient DNA transfection, cells were seeded (21,000 cells/cm2) in 24-well plates 
in culture medium. The next day, the cells were transfected with plasmid DNA 
complexed with JetPrime (PolyPlus) in a 1:2 mixture (DNA/JetPrime). For RUSH 
experiments, 0.5 Pg of DNA was used. 0.25 Pg of DNA was used for all other 
experiments. 6 h after DNA transfection, cells were returned to normal growth 
conditions and then fixed for imaging 24 h later.  
 
Antibodies and reagents 
Primary antibody concentrations ranged from 1-5 ȣg/mL for immunoblotting and IF 
assays. Mouse monoclonal anti-CHC17 antibodies (TD.1 (Nathke et al., 1992) and 
X22 (Brodsky, 1985)), and affinity-purified rabbit polyclonal antibody specific for 
CHC22 and not CHC17 (Vassilopoulos et al., 2009) were produced in the Brodsky 
laboratory. Mouse monoclonal anti-p115 antibody (clone 7D1) has been described 
(Waters et al., 1992). Mouse monoclonal anti-GGA2 was a gift from Dr Juan 
Bonifacino (US National Institutes of Health, Bethesda, MD, USA). Rabbit polyclonal 
antibody anti-L.p. was a gift from Dr Craig Roy (Yale University, New Haven, CT, 
USA). Mouse monoclonal antibody anti-L.p. was made in the Mukherjee lab. 
Commercial sources of antibodies were as follows: Rabbit polyclonal anti-CHC17 
(ab21679 Abcam), rabbit polyclonal anti-CHC22 antibody (22283-1-AP Proteintech), 
mouse monoclonal anti-ș-COP (clone maD, G6160 Sigma), rabbit polyclonal anti-
IRAP (#3808, Cell Signaling Technology), rabbit monoclonal anti-IRAP (clone D7C5, 
#6918, Cell Signaling Technology), rabbit polyclonal anti-phospho AKT Ser473 
(#9271, Cell Signaling Technology), rabbit polyclonal anti-phospho-AS160 Thr642 
(#4288, Cell Signaling Technology), rabbit polyclonal anti-AS160 (#2447, Cell 
Signaling Technology), goat polyclonal anti-GLUT4 (C-20, sc-1608 Santa-Cruz 
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Biotechnologies), Rabbit anti-GLUT4 (235003 Synaptic Systems), mouse 
monoclonal anti-calreticulin (clone FMC75, ADI_SPA-601 Stressgen Bioreagents), 
sheep polyclonal anti-TGN46 (AHP500G, Biorad), goat polyclonal anti-GM130 (P-20, 
sc-16268 Santa-Cruz Biotechnologies), sheep polyclonal anti-Sec22b (AHP500G, 
Creative Diagnostics), mouse monoclonal anti-ERGIC-53 (clone 2B10, TA502110 
OriGene), rabbit polyclonal anti-ERGIC-53 (E1031, Sigma), rabbit monoclonal anti-
LMAN1 (clone EPR6979, ab125006 Abcam), rabbit polyclonal anti-sortilin (ab16640, 
Abcam), Rabbit polyclonal anti-sortilin (12369-1-AP, Proteintech), mouse monoclonal 
anti-sortilin (clone EPR15010, ab188586, Abcam), mouse monoclonal anti-STX-6 
(clone 30/Syntaxin 6, AF5664 Becton Dickinson), mouse monoclonal anti-ș actin 
(clone AC-15, A5441 Sigma), mouse monoclonal anti-HA (clone 16B12, Covance), 
mouse monoclonal anti-MHCI W6/32 (produced from the hybridoma in the Brodsky 
lab) has been described (Barnstable et al., 1978), goat polyclonal anti-Rab1 
(orb153345, Biorbyt), chicken anti-GFP (A10262, Invitrogen). The commercial anti-
CHC22 from Proteintech was confirmed in our laboratory to be specific for CHC22 
and not CHC17 (Fig. S1 A). For IF, secondary antibodies coupled to FITC, Alexa 
Fluor 488, Alexa Fluor 555, Alexa Fluor 562 or to Alexa Fluor 647 (Thermo Fisher 
Scientific) were used at 1:500. For Western blotting, antibodies coupled to HRP 
(Biorad) were used at 1:10,000. Brefeldin A (BFA) was from Sigma.  
 
Legionella pneumophila 
WT and ǻGRW$ Legionella VWUDLQVZHUHJLIWV IURP'U&UDLJ 5R\¶V <DOH8QLYHUVLW\
The parental strain (wild type) was L.p. serogroup 1 strain L.p.01, and the variant 
strain ǼdotA were isogenic mutants described previously (Berger et al., 1994; 
Zuckman et al., 1999). Single colonies of L.p. were isolated from charcoal yeast 
extract plates after growth for 2 days at 37ºC. DsRed-expressing WT L.p. were 
grown on charcoal yeast extract plates containing 500 PM isopropyl+- o-
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thiogalactopyranoside (IPTG) for 2 days at 37ºC to induce expression of the 
fluorescent protein. 
 
Infection and analysis of replicative vacuoles  
A549 cells were seeded 105 cells per 2 cm2 on coverslips. Cells were infected at a 
multiplicity of infection (MOI) of 25 with WT or ǼdotA L.p. strains. Immediately after 
adding L.p. to the medium, cells were centrifuged at 400 x g for 15 min, then left at 
37ºC for an additional 45 min. Cells were then washed 3X with PBS and incubated in 
growth medium for the indicated time. To analyse replicative vacuoles, cells were 
directly infected with WT or ǼdotA L.p. at a MOI of 50 for 1h for labelling with 
antibodies or transfected with siRNA (20 nM) or with plasmids encoding HA-GLUT4-
GFP, CHC22-GFP or CHC17-GFP 72h before infection. Infected cells (transfected or 
not transfected) were incubated for 8h post-infection, then washed 3X with PBS, 
fixed with 2.5% paraformaldehyde (PFA) for 30 min and labelled with antibody to 
detect bacteria for counting the number per replicative vacuole and with antibodies to 
identify compartment markers. 
 
Immunofluorescence 
Cells grown on 1.5# glass coverslips (Warner Instruments) were washed (PBS, 4oC), 
fixed (2-4% PFA, 30 min, 4oC), permeabilized and blocked (PBS 0.5% saponin, 2% 
bovine serum albumin) for 1 hour at room temperature (RT). Cells were then 
incubated with primary antibodies (overnight, 4ºC), washed (5X, PBS, 4oC) and 
incubated with species-specific secondary antibodies coupled to fluorophores 
(Thermo Fisher Scientific). Cells were then washed (5X, PBS, 4oC) and coverslips 
mounted on microscope slides using Prolong Antifade Diamond kit (Thermo Fisher 
Scientific). Samples were imaged at room temperature using a Leica TCS SP8 
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hybrid detectors (HyD) and one PMT, a 63X (1.40 NA) HC Plan-Apo CS2 oil-
immersion objective and five laser lines. Dyes were sequentially excited at 405 nm 
(DAPI), 488 nm (GFP, Alexa Fluor 488), 543 nm (Alexa 555), 561 nm (Alexa 568), 
and 633 nm (Alexa 647). Multicolor images (1024 x 1024 pixels) were saved as TIFF 
files in Leica LAS X Software (Leica) and input levels were adjusted using ImageJ 
(v2.0.0-rc-69/1.52p, US National Institutes of Health, NIH). For each cell, individual 
marker fluorescence was measured in separate channels, signals were adjusted to 
their dynamic ranges and labeling detected in individual channels is shown in black 
and white in figure panels. Merged images are presented in pseudo-color as 
described in the legends. Degree of marker overlap in individual cells was 
determined by Pearson¶s correlation coefficients determined using the colocalization 
plugin on ImageJ.  
 
Structured Illumination Microscopy (SIM) 
Sample preparation (fixation and staining) steps were identical to confocal 
microscopy. Sample acquisition was performed on a Zeiss Elyra PS.1 microscope 
(Axio Observer.Z1 SR, inverted, motorized) through a 100X alpha Plan-Apochromat 
DIC M27 Elyra lens (oil-immersion, 1.46 NA). Fluorophore excitation was performed 
with a 50 mW HR diode emitting at 350 nm (BP 420-480/LP 750 filter), and a 200 
mW HR diode emitting at 488 nm (BP 495-550/LP 750 filter), a 200 mW HR Diode 
Pumped Solid State laser emitting at 561 nm (BP 470-620/LP 750 filter) and a 260 
mW HR diode emitting at 642 nm (LP 655 filter). Acquisition was performed using a 
pco.egde sCMOS camera and post-acquisition processing (channel alignment) was 
performed on the ZEN Black software Version 11.0.2.190. 
 
GLUT4 internalization experiments 
The GLUT4 internalization protocol was adapted from previous work (Foley and Klip, 
2014). Briefly, HeLa-GLUT4 cells were seeded on coverslips in 24-well plate and 
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grown to 80% confluency. On the day of the experiment, cells were washed (3X, 
PBS, 37oC) and serum starved 2 hours. Cell surface HA-GLUT4-GFP was labeled on 
ice for 30 min with mouse monoclonal anti-HA antibody. After washing (5X, PBS, 
4oC), cells were placed in serum-free medium (37oC) for indicated times. Cells were 
then washed (3X, PBS, 4oC), fixed and processed for immunofluorescence detection 
of internalized anti-HA antibody. 
 
GLUT4 translocation assay using flow cytometry 
HeLa-GLUT4 cells were seeded in 6-well plates and grown to 95% confluency. On 
the day of experiment, cells were washed (3X, PBS, 37oC), serum-starved (2 hours), 
then treated with insulin to a final concentration of 170 nM or the same volume of 
vehicle (water) diluted in serum-free medium for 15 minutes, 37°C. Cells were then 
placed on ice and rapidly washed (3X, PBS, 4°C) and fixed (PFA 2 .5%, 30 min). 
After fixation, cells were washed (3X, PBS, RT) then blocked for 1 hour (PBS 2% 
BSA, RT) before incubation with monoclonal anti-HA antibody (45 min, RT) to detect 
surface GLUT4. After incubation, cells were washed (5X, PBS, RT) and incubated 
with Alexa Fluor 647-anti-mouse Ig (45 min, RT). Cells were then washed (5X, PBS, 
RT), gently lifted using a cell scraper (Corning), pelleted (200xg, 10 min) and re-
suspended (PBS, 2% BSA, 4°C). Data was acquired with Diva acquisition software 
by LSRII flow cytometer (Becton Dickinson) equipped with violet (405 nm), blue (488 
nm) and red (633 nm) lasers. Typically, 10,000 events were acquired and Mean 
Fluorescence Intensity (MFI) values for surface GLUT4 (Alexa Fluor 647) and total 
GLUT4 (GFP) were recorded using 660/20 and 530/30 filters, respectively. Post-
acquisition analysis was performed using FlowJo software (Treestar) where debris 
was removed by FSC/SSC light scatter gating then fluorescence histograms were 
analyzed. The ratio of surface to total MFI was calculated to quantify the extent of 
GLUT4 translocation.  
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Translocation assay using immunofluorescence 
To test the effect of insulin and CHC22 depletion on the surface expression of 
endogenous Class I MHC molecules, cells were treated with siRNA targeting CHC22 
or with control siRNA (as elsewhere in the Methods) then serum starved (1h, 37ºC) 
before insulin stimulation (15 minutes, 170 nM, 37ºC). Cells were then placed on ice, 
washed (PBS, 4ºC) and incubated with primary antibodies (1h, 4ºC), then washed 
(PBS, 4oC), fixed (2.5% PFA, 30 min, 4oC), washed (PBS, 4ºC) and incubated with 
fluorescent secondary antibodies (30 min, 4ºC). Cells were then washed (5X, PBS, 
4oC) and coverslips were mounted on microscope slides using Prolong Antifade 
Diamond mounting medium (Thermo Fisher Scientific). 
 
RUSH assay 
HeLa cells were seeded at 30,000 cells/cm2 on coverslips. The next day, cells were 
transfected with 0.5 µg of HA-GLUT1-SBP-GFP or HA-GLUT4-SBP-GFP plasmids 
for 6h, then switched to fresh medium. The next day, cells were treated with 40 µM 
biotin for the indicated times. Cells were then quickly placed on ice, washed (3X, 
PBS, 4oC), fixed (2.5% PFA, RT) and processed for immunofluorescence. For video-
microscopy acquisition, cells were transfected simultaneously with HA-GLUT1-SBP-
mCherry (2 µg) and HA-GLUT4-SBP-GFP (2 µg) using the calcium phosphate 
precipitation method (Jordan et al., 1996) and imaged 20h later on a spinning disk 
confocal microscope. Real-time imaging was performed at 37°C on an Eclipse 80i 
(Nikon) equipped with a spinning disk head CSU-X1 (Yokogawa), an Ultra897 iXon 
camera (Andor) and a 60x CFI Plan Apo VC (1.4 NA). Cells were imaged in pre-
ZDUPHG /HLERYLW]¶V PHGLXP 7KHUPR Fisher Scientific) in an L-shaped tubing 
Chamlide chamber (Live Cell Instrument). Image acquisition was performed using 
MetaMorph software (Gataca Systems). Maximum projection of the z-slices was 
performed using ImageJ. 
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Alkaline phosphatase secretion assay 
HeLa-GLUT4 cells were seeded in 96-well plates, grown to 80% confluency and 
were transfected the next day with 20 nM targeting or control siRNA. After 48h, cells 
were transfected with the plasmid encoding secreted alkaline phosphatase. After 
24h, fresh medium was added to the culture and 8h later, the medium was harvested 
and the cells lysed. Alkaline phosphatase activity in the harvested medium and cell 
lysate was assessed using the Phospha-Light System kit (Applied Biosystems), 
IROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXFWLRQVDQGGHWHFWHGZLWKDOXPLQRPHWHU(Varioskan 
LUX multimode multiplate reader, Thermo Fisher Scientific). The alkaline 
phosphatase secretion index was determined by calculating the ratio of alkaline 
phosphatase activity detected in the medium (secreted) to total alkaline phosphatase 
activity in the culture (medium plus cell lysate activity). 
 
Brefeldin A treatment 
HeLa-GLUT4 or LHCNM2 myoblasts were grown on coverslips and exposed to BFA 
(10 µg/mL, 1h, 37°C) or vehicle in starvation medium (DMEM only) . During the last 
15 minutes, cells were incubated with insulin (170 nM, 15 minutes) or vehicle. Cells 
were then washed (3X, PBS, RT) and processed for immunofluorescence. 
 
Preparation of clathrin-coated vesicles (for anti-CHC22 characterization)  
Clathrin coated vesicles (CCV) preparation was adapted from Keen et al. (Keen et 
al., 1979). Briefly, pig brains were blended in buffer A (100mM MES, 1mM EDTA, 0.5 
mM MgCl2) supplemented with 0.5 mM phenylmethane sulfonyl fluoride (PMSF). 
The preparation was centrifuged at 8,000 rpm (JA-17 rotor, Beckman) at 4°C for 30 
min, then the supernatant was filtered to remove particles and centrifuged at 40,000 
rpm (45 Ti rotor, Beckman) at 4°C for 60 min to pellet the CCVs. A small volume of 
buffer A supplemented with 0.02 mM PMSF was added to the CCV pellets before 
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homogenization with a potter S homogenizer. A solution of 12.5% Ficoll 12.5% 
sucrose was added 1:1 to the CCV suspension and gently mixed. The CCV 
preparation was then centrifuged at 15,000 rpm (JA-17 rotor, Beckman) at 4°C for 40 
min. The supernatant was collected, diluted 5-fold in buffer A supplemented with 1 
mM PMSF and centrifuged 40,000 rpm (45 Ti rotor, Beckman) for 60 min at 4°C to 
pellet vesicles. The pellet was resuspended in buffer A for Tris extraction. Finally, 
CCVs were purified by gel filtration (Superose 6, GE Life Science) and stored at -
&LQ(?P07ULV±+&OS+(?  
 
Purification of hub CHC22 (for anti-CHC22 characterization) 
The CHC22 Hub fragment (residues 1074-1640) (Liu et al., 2001) was produced in 
BL21(DE3) bacteria (Novagen) by induction with 1 mM IPTG for 24 hr at 12°C. 
Bacterial pellets were resuspended in LysI (1M NaCl pH=8, 20 mM imidazole in PBS) 
supplemented with 1 mM PMSF, protease inhibitors (1 tab/10 mL, Roche), 40 ȣ
g/mL lysozyme, 0.1% E-mercaptoethanol (Sigma). Then LysII (1M NaCl, 0.5M 
guanidine HCl, 0.4% Triton X100 in PBS) was added at 1:1.25 (LysI:LysII) ratio and 
samples were spun at 40,000 rpm for 30 min at 4°C. Supernatant was exposed to a 
Ni+ affinity NTA column, which was then washed with LysI, and bound protein eluted 
with 1M NaCl pH8, 0.5M imidazole in PBS. 
 
Immunoblotting 
Protein extracts from cells were quantified by BCA (Pierce), separated by SDS-
PAGE (10% acrylamide), transferred to nitrocellulose membrane (0.2 ȣm, Biorad) 
and labeled with primary antibodies (1-5 ȣg/mL), washed and labeled with species-
specific horseradish peroxidase-conjugated secondary antibodies (Thermo Fisher 
Scientific). Peroxidase activity was detected using Western Lightning 
Chemiluminescence Reagent (GE Healthcare). The molecular migration position of 
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transferred proteins was compared to the PageRuler Prestain Protein Ladder 10 to 
170 kDa (Thermo Fisher Scientific). Signal quantification was performed using Image 
J software (NIH).  
 
Immunoprecipitation 
Confluent cells from a 500 cm2 plate were scraped off the plate, washed in ice-cold 
PBS and pelleted (300 g, 8 min, 4ºC). The pellets were resuspended in ice-cold lysis 
buffer (NaCl 150 mM, HEPES 20 mM, EDTA 1 mM, EGTA 1 mM, Glycerol 10% 
(V/V), NP-40 0.25% (V/V)) supplemented with protease (1 tab/10mL, Roche) and 
phosphatase (Na4VO3 2 mM) inhibitors. Cell suspensions were mechanically sheared 
(over 25 passages through a 27G needle), sonicated and centrifuged (500 g for 10 
min, 4ºC) to remove nuclei. Five to 10 µg of specific anti-CHC22 (Proteintech) and 
CHC17 (X22) antibodies were incubated with 7 mg of pre-cleared post-nuclear 
supernatants (overnight, 4ºC). The samples were then incubated with washed protein 
G sepharose (PGS, 25 µL, GE Healthcare) for 1h (4ºC) before three consecutive 
washing steps in lysis buffer. Pelleted PGS was resuspended in 30 µL of 1X Laemmli 
sample buffer and subjected to SDS- PAGE and immunoblotting. Species-specific 
HRP-conjugated Trueblot secondary antibodies (Rockland) were used for 
immunoblotting IP experiments. 
 
Statistical analyses 
All calculations and graphs were performed with Microsoft Excel and GraphPad 
Prism softwares. P-values were calculated using unpaired, two-WDLOHG 6WXGHQW¶V W-
tests or one-way ANOVA followed by Tukey, Dunnett, Bonferroni RU6LGDN¶VPXOWLSOH
comparisons test. Data distribution was assumed to be normal but this was not 
formally tested. Detailed statistical information including statistical test used, number 
of independent experiments, p values, definition of error bars is listed in individual 
figure legends. All experiments were performed at least three times, except for the 
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immunoblots shown in Figs. 1 B and 7 A and the infection experiment shown in Fig. 
S4 D, which were performed twice. Immunofluorescence stainings showed in Figs. 
S3 A, B were performed once. 
 
Summary of Supplemental material  
This manuscript contains 2 videos and 5 supplemental figures (Fig. S1-S5). 
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Figure Legends 
Figure 1: HeLa-GLUT4 cells have a functional GLUT4 trafficking pathway that 
requires CHC22. 
(A) Representative images of GLUT4 (exofacial haemagglutinin (HA)-tag, internal 
GFP tag) in HeLa-GLUT4 cells before (basal) or after insulin treatment. GLUT4 at the 
plasma membrane was detected by immunofluorescence (IF) after surface labeling 
with anti-HA monoclonal antibody (red). Total GLUT4 (green) was detected by GFP 
tag. Arrows show the GLUT4 storage compartment. Arrowheads point to peripheral 
GLUT4 YHVLFOHV 6FDOH EDUV  ȝP % /HIW SDQHO ± Representative FACS 
histogram of surface GLUT4 fluorescence intensities (signal from anti-HA labeling) 
before (basal) and after insulin treatment (Ins). Middle panel ± Quantification of 
surface:total GLUT4 (HA:GFP mean fluorescence intensity signals). Data expressed 
as mean ± SEM, N=3, 10,000 cells acquired per experiment. Two-tailed unpaired 
6WXGHQW¶V W-test with equal variances, **p<0.01. Right panel ± Representative 
immunoblot for phosphorylated AKT (p-AKT), phosphorylated AS160 (p-AS160), total 
$6 DQG ȕ-actin in HeLa-GLUT4 cells before and after insulin treatment. The 
migration position of molecular weight (MW) markers is indicated at the left in 
kilodaltons (kDa). (C) Representative images of total GLUT4 (GFP tag, green) and 
Major Histocompatibility Complex I molecules (MHCI, blue) before (basal) or after 
insulin treatment in HeLa-GLUT4 cells transfected with non-targeting control siRNA 
(siControl) or siRNA targeting CHC22 (siCHC22). Scale bars: 8 µm. (D) 
Representative FACS histograms of surface GLUT4 fluorescence intensity (signal 
from anti-HA labeling) in HeLa-GLUT4 cells transfected with siControl or siRNA 
siCHC22 before (red) or after treatment with insulin (blue). Histograms are extracted 
from the experiment quantified in Fig. 8 A. (E) Representative IF staining for 
internalized surface-labeled GLUT4 (HA-tag, blue) and syntaxin 6 (STX-6, red) for 
HeLa-GLUT4 cells at 0, 10 or 30 minutes after insulin treatment. Total GLUT4 is 
GHWHFWHG E\ *)3 WDJ JUHHQ 6FDOH EDUV  ȝP ) 3HDUVRQ¶V RYHUODS
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quantification for labeling of STX-6 and HA-tag. Data expressed as mean ± SEM, 
N=3, 14-19 cells per experiment. One-way analysis of variance (ANOVA) followed by 
%RQIHUURQL¶V PXOWLSOH FRPSDULVRQ SRVW-hoc test ****p<0.0001. (G) Left panel ± 
representative Structured Illumination Microscopy (SIM) image of a HeLa-GLUT4 cell 
stained for STX-6 (red). Total GLUT4 (green) was detected by GFP tag. The gray 
circle delineates the nucleus (N) and the white square delineates the magnified area 
displayed in the right panel image. Scale barsȝP, magnified image: 1 µm. Right 
panel ± the white dashed line in the magnified area spans the segment for which 
fluorescence intensities for GLUT4 and STX-6 are plotted below, in green and red, 
respectively. Arrowheads indicate areas of overlap. (H) Representative IF staining for 
CHC17 (red) and CHC22 (blue) in HeLa-GLUT4 cells transfected with non-targeting 
siControl or siRNA targeting CHC17 (siCHC17) or siCHC22, with GLUT4 detected by 
GFP tag (green). Arrows point to a CHC22-GHSOHWHG FHOO 6FDOH EDUV  ȝP IRU
VL&RQWURODQGVL&+&DQGȝPIRUVL&+&0HUJHGLPDJHVLQ$&(*
(H) show red/green overlap in yellow, red/blue overlap in magenta, green/blue 
overlap in cyan, and red/green/blue overlap in white. 
 
Figure 2: Newly synthesized GLUT4 is delayed in the early secretory pathway 
compared to GLUT1. 
(A) Representative stills extracted from Video 1 showing a HeLa cell expressing the 
endoplasmic reticulum (ER) Ii-hook fused to streptavidin along with HA-GLUT1-SBP-
mCherry (GLUT1, red) and HA-GLUT4-SBP-GFP (GLUT4, green). The intracellular 
traffic of GLUT1-mCherry and GLUT4-GFP was simultaneously tracked for 1h after 
biotin addition released them from the ER. Upon ER exit, both GLUT1 and GLUT4 
accumulated in the perinuclear region of the cell (yellow). From 26 min onwards, 
highly mobile GLUT1 vesicles (arrowheads) were visible (red) while GLUT4 
remained perinuclear. Scale bar: 10 µm.  (B, D, F, H, J) Representative 
immunofluorescence staining for GLUT1-SBP-GFP or GLUT4-SBP-GFP (detected 
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with anti-GFP antibody, green), CHC22 (red) and (B) calnexin (CNX, blue), (D) 
ERGIC-53 (blue), (F) p115 (blue), (H) GM130 (blue) or (J) TGN46 (blue) in HeLa 
cells expressing HA-GLUT1-SBP-GFP or HA-GLUT4-SBP-GFP along with the ER Ii-
hook. Traffic of GLUT4 and GLUT1 was tracked at 0, 15, 30 and 60 minutes after 
release from the ER by biotin. Arrows point to GLUT1 detected at the plasma 
membrane and arrowheads point to GLUT1-positive endosomal structures. Merged 
images show red/green overlap in yellow, red/blue overlap in magenta, green/blue 
overlap in cyanDQGUHGJUHHQEOXHRYHUODSLQZKLWH6FDOHEDUVȝP&(*,
. / 3HDUVRQ¶V RYHUODS EHWZHHQ */87 RU */87 DQG CNX, ERGIC-53, p115, 
GM130, TGN46 or CHC22 at different time-points post-ER release. Data expressed 
as mean ± SEM, N=3-4, 10-46 cells per experiment. One-way analysis of variance 
$129$ IROORZHGE\6LGDN¶VPXOWLSOHFRPSDULVRQSRVW-hoc test *p<0.05, **p<0.01, 
****p<0.0001 to test differences between GLUT1 and GLUT4 overlap with markers at 
HDFK WLPH SRLQW 0 3HDUVRQ¶V RYHUODS EHWZHHQ &+C22 and GLUT4, ER marker 
calreticulin, ERGIC markers p115 and ERGIC-53, cis-Golgi marker GM130 or trans-
Golgi marker TGN46 in HeLa-GLUT4 from images taken by confocal microscopy 
(corresponding representative immunofluorescence staining in Fig. S1). Data 
expressed as mean ± SEM, N=3, 4-10 cells across 3 independent samples. 
 
Figure 3: CHC22 is localized at the ER-to-Golgi Intermediate Compartment in 
HeLa GLUT4 and human myotubes. 
(A and B) Representative Structured Illumination Microscopy of a HeLa-GLUT4 cell  
(HeLa-G4) (A) and the human skeletal muscle cell line hSkMC-AB1190-GLUT4 
(hSkMC) (B) stained for CHC22 (red) and p115 (blue). The gray circles delineate the 
nuclei (N). Muscle cell staining with each antibody is shown in black on white below 
WKH FRORU LPDJHV 6FDOH EDUV  ȝP & DQG ' 5HSUHVHQWDWLYH 6WUXFWXUHG
Illumination Microscopy of the perinuclear region of HeLa-GLUT4 cells and hSkMC-
AB1190-GLUT4 stained for CHC22 (red) and p115 (C), ERGIC-53 (blue) (D). The 
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solid gray lines delineate the nuclear border (N). The dashed white lines span the 
segment for which fluorescence intensities for GLUT4 (green), CHC22 (red) and 
p115, ERGIC-53 (blue) were plotted. Arrowheads indicate areas of peak overlap. 
6FDOH EDUV  ȝP In A, B, C and D, GLUT4 (green) was detected by GFP tag in 
HeLa-GLUT4 or immunostained with anti-GFP antibody in hSkMC-AB1190-GLUT4. 
Merged images show red/green overlap in yellow, red/blue overlap in magenta, 
green/blue overlap in cyan, and red/green/blue overlap in white. 
 
Figure 4: The CHC22 compartment is localized proximal to the trans-Golgi 
Network and does not overlap with the cis-Golgi. 
(A, B and C) Representative Structured Illumination Microscopy of the perinuclear 
region of HeLa-GLUT4 cells (HeLa-G4) and hSkMC-AB1190-GLUT4 (hSkMC) 
stained for CHC22 (red) and GM130 (A), TGN46 (B) and syntaxin 6 (STX-6, blue) 
(C). The solid gray lines delineate the nuclear border (N). The dashed white lines 
span the segment over which fluorescence intensities for GLUT4 (green), CHC22 
(red) and GM130, TGN46 and STX-6 (blue) were plotted. 6FDOHEDUVȝPIn A, B 
and C, GLUT4 (green) was detected by GFP tag in HeLa-GLUT4 in HeLa-GLUT4 or 
immunostained using an anti-GFP antibody in hSkMC-AB1190-GLUT4. Merged 
images show red/green overlap in yellow, red/blue overlap in magenta, green/blue 
overlap in cyan, and red/green/blue overlap in white. 
 
Figure 5: CHC22 mediates membrane traffic from the ERGIC to the Legionella 
pneumophila replicative vacuole, which acquires some GLUT4 pathway 
markers. 
(A) Representative images of Legionella pneumophila (L.p.)-infected A549 cells 
transiently transfected with GFP-tagged CHC22 or CHC17 (green). One hour after 
infection with either wild type (WT) or mutant ǼdotA L.p. (MOI=50), bacteria were 
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detected by immunofluorescence (IF, red). Arrows point to L.p. and boxed inserts 
(upper right or left) show the L.p. UHJLRQDW;PDJQLILFDWLRQ6FDOHEDUVȝPIRU
cells expressing CHC22-*)3 DQG  ȝP IRU FHOOV H[SUHVVLQJ &+&-GFP. (B) 
Quantification of the proportion of L.p. vacuoles positive for CHC22 or CHC17. Data 
expressed as mean ± SEM, N=3, 4 to 35 vacuoles counted per experiment 
performed as represented in (A). One-way analysis of variance (ANOVA) followed by 
%RQIHUURQL¶V PXOWLSOH FRPSDULVRQ SRVW-hoc test ***p<0.001. (C) Representative 
images of A549 cells infected with WT L.p. (MOI=50) immunolabeled for endogenous 
CHC22 or CHC17 (red) and L.p. (green) by IF. Arrows point to L.p., dashed lines 
delineate cell borders. Scale bars  ȝP (D) Quantification of the proportion of 
replicative vacuoles (8 hours post-infection) containing 1, 2 to 4, or more than 4 WT 
or ǼdotA L.p. after treatment with siRNA targeting CHC22 (siCHC22) or CHC17 
(siCHC17) or non-targeting siRNA (siControl). Data expressed as mean ± SEM, N=3, 
over 140 vacuoles counted per experiment. One-way ANOVA followed by 
%RQIHUURQL¶V PXOWLSOH FRPSDULVRQ SRVW-hoc test was performed to compare the 
number of cells with a vacuole containing more than 4 bacteria. ****p<0.0001 versus 
siControl-transfected cells infected with WT L.p.. ++++p<0.0001 versus siControl-
transfected cells infected with ǼdotA L.p.  (E) Quantification of the proportion of L.p. 
vacuoles positive for GLUT4-GFP, p115, GGA2, sortilin, IRAP or Rab1 1h after 
infection with WT or ǼdotA L.p. in HeLa cells transiently expressing FcJRII (needed 
for L.p. infection) (Arasaki and Roy, 2010). Data expressed as mean ± SEM, N=3, 4 
to 50 vacuoles counted per experiment. Two-WDLOHG XQSDLUHG 6WXGHQW¶V W-test with 
equal variances: *p<0.05, **p<0.01, ***p<0.001. (F-I) Representative 
immunofluorescence of HeLa cells one hour after infection with either wild type (WT) 
or mutant ǼdotA L.p. (MOI=50) stained for L.p. (red) and sortilin (F), IRAP (G), 
GGA2 (H), or p115 (green) (I). Hoechst stains the nuclei (blue). Arrows point to L.p.-
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FRQWDLQLQJ YDFXROHV 6FDOH EDUV  ȝP 0HUJHG LPDJHV in (A), (C), (F-I) show 
red/green overlap in yellow. 
 
Figure 6: CHC22 interacts with p115 and each influences stability of different 
partners involved in GLUT4 membrane traffic. 
 (A-D) Representative immunoblots of immunoprecipitates of CHC22, CHC17 (A-D) 
or sortilin (C and D) from HeLa-GLUT4 cells (A and C) and hSKMC-AB1190 (B and 
D) immunoblotted for CHC22, CHC17, p115, GLUT4 and Sortilin. The position of 
molecular weight (MW) markers is indicated in kilodaltons (kDa) at the left. 
(E-G) Representative immunoblots of HeLa-GLUT4 cells transfected with siRNA 
targeting CHC22, CHC17 (E, F) or p115 (F, G) or with non-targeting control siRNA 
(40 nM for 72h) showing levels of CHC22, GLUT4, GGA2, CHC17, p115, sortilin and 
E-actin (E, G) or levels of IRAP and E-actin (F). The position of molecular weight 
(MW) markers is indicated in kilodaltons (kDa) at the left. In HeLa-GLUT4 cells, 
GLUT4 is tagged, altering its migration compared to muscle cell GLUT4. (H-J) 
Quantifications of immunoblot signals as shown in (E-G). Blot signals were 
normalized to E-actin for each experiment and the fold change (negative values 
indicate decrease and positive values indicate increase) relative to the normalized 
signal in control siRNA-treated cell lysates is plotted. Data expressed as mean ± 
SEM, N=7-8. Two-WDLOHG XQSDLUHG 6WXGHQW¶V W-WHVW ZLWK :HOFK¶V FRUUHFWLRQ ZKHUH
variances were unequal: *p<0.05; ***p<0.001, ****p<0.0001.  
 
Figure 7: Depletion of CHC22 or p115, but not GM130, sortilin or IRAP disrupt 
perinuclear targeting of GLUT4. 
(A) Immunoblotting for CHC22, CHC17, p115, GM130 and E-actin after transfection 
of HeLa-GLUT4 cells with siRNA targeting CHC17, CHC22, p115, GM130, sortilin, 
IRAP or with non-targeting control siRNA (siControl). The position of molecular 
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weight (MW) markers is indicated in kilodaltons (kDa) at the left. (B) Representative 
immunofluorescence (IF) staining for CHC22 (red) and p115 (blue) in HeLa-GLUT4 
cells after siRNA transfection as in (A), with GLUT4 detected by GFP tag (green). N, 
nuclei. Arrow points to CHC22-GHSOHWHGFHOO6FDOHEDUVȝP&5HSUHVHQWDWLYH
IF staining for GM130 (yellow), p115 (red) and CHC22 (blue) in HeLa-GLUT4 cells 
after treatment with siRNA targeting GM130 or with control siRNA, with GLUT4 
detected by GFP tag (green). Individual antibody staining is shown in black and 
white, while the merged image shows all four colors with overlap indicated as below. 
6FDOHEDUVȝP'DQG(5HSUHVHQWDWLYH,) staining for GLUT4 (green), CHC22 
or sortilin (red) and p115 (blue) in HeLa-GLUT4 cells after treatment with siRNA 
targeting sortilin or IRAP or with non-targeting control 6FDOH EDUV  ȝP Merged 
images show red/green overlap in yellow, red/blue overlap in magenta, green/blue 
overlap in cyan, and red/green/blue overlap in white. 
 
Figure 8: Formation of the human insulin-responsive GLUT4 pathway involves 
membrane traffic from the ERGIC and supports a model for two routes to 
GLUT4 sequestration.    
 (A and B) Insulin-stimulated GLUT4 translocation in HeLa-GLUT4 cells as quantified 
by FACS analysis of surface:total GLUT4. Cells were pre-treated with siRNA 
targeting CHC22, CHC17, p115, GM130, sortilin, IRAP, sortilin plus IRAP, or with 
non-targeting control siRNA (siCon) as in Fig. 7 A, then incubated with (+) or without 
(-) insulin (Ins). For the experiments in (A), data is expressed as mean ± SEM, N=9, 
10,000 cells acquired per experiment. One-way ANOVA follRZHG E\ %RQIHUURQL¶V
multiple comparison post-hoc test **p<0.01, ***p<0.001, ****p<0.0001 versus 
untreated (-). For the experiments in (B), data is expressed as mean ± SEM, N=7, 
10,000 cells acquired per experiment. One-ZD\ $129$ IROORZHG E\ %RQIHUURQL¶V
multiple comparison post-hoc test *p<0.05, **p<0.01, ***p<0.001 versus untreated. 
(C) Proposed model for the roles of CHC22 in the human GLUT4 pathway. Newly 
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synthesized GLUT4 traffics from the endoplasmic reticulum (ER) to the ER-to-Golgi 
Intermediate Compartment (ERGIC). At the ERGIC, a complex forms between IRAP 
and p115 that promotes binding of CHC22 clathrin and sequesters GLUT4 through 
its IRAP interaction (Shi et al., 2008) (box A). Formation of the CHC22 clathrin coat 
at the ERGIC then facilitates sorting of GLUT4 to the intracellular region where 
GLUT4 storage vesicles (GSV) and insulin responsive GLUT4 vesicles (IRV) are 
formed. After insulin-mediated GLUT4 translocation and GLUT4 re-uptake (by 
CHC17 clathrin), a complex forms (box B) between endosomal GLUT4, sortilin and 
the clathrin adaptor GGA2, which promotes CHC22 recruitment. Endosomal GLUT4 
sorting also involves clathrin adaptor AP1 (Blot and McGraw, 2008; Gillingham et al., 
1999), which interacts with CHC22 further participating in its recruitment to 
endosomes (Vassilopoulos et al., 2009). Formation of the CHC22 coat on sorting 
endosomes facilitates GLUT4 traffic to the TGN via the retrograde pathway, enabling 
replenishment of the intracellular GSV/IRV pool. The GLUT4 storage compartment 
(GSC) comprises the entire tubulo-vesicular complex involved in sorting and 
sequestration of GLUT4, with CHC22 mediating two pathways to the human GSC. 
 
SUPPLEMENTARY INFORMATION 
 
Figure S1: Immunofluorescence localization of CHC22 at the ER-to-Golgi 
Intermediate Compartment in HeLa-GLUT4 cells and in human skeletal muscle 
cells. 
(A) Immunoblots (left) for CHC17 (X22 antibody) or CHC22 (CLTCL1 antibody from 
Proteintech) of clathrin coated vesicles (CCV) purified from pig brain containing only 
CHC17 or of cell lysate from bacteria expressing low levels of the hub fragment 
(residues 1074-1640) of CHC22 (hub22). Ponceau staining for proteins (Pro) is 
shown to the right of each antibody blot.  The migration of molecular weight (MW) 
markers is indicated at the left in kilodaltons (kDa). (B) Representative confocal 
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microscopy immunofluorescence (IF) imaging of CHC22 (red or blue), p115 (red or 
blue) and GLUT4 (green) in HeLa-GLUT4 cells (top panel) or LHCNM2 myotubes 
(bottom panel). (C) Representative IF staining for CHC22 (blue), ERGIC-53 (red) and 
GLUT4 (green) in HeLa-GLUT4 cells (top panel) or LHCNM2 myotubes (bottom 
SDQHO6FDOHEDUVȝPIRU+H/D-*/87FHOOVDQGȝPIRULHCNM2 myotubes in 
(B) and (C). (D) Representative IF staining for CHC22 (blue), GM130 or TGN46 (red) 
and GLUT4 (GFP, green) in HeLa-*/87 FHOOV 6FDOH EDUV  ȝP () 
Representative IF staining for CHC22 (blue), GM130 or TGN46 (green) and p115 
UHG LQ/+&10P\RWXEHV6FDOHEDUVȝP )5HSUHVHQWDWLYH ,)VWDLQLQJ IRU
CHC22 (blue), calreticulin (red) and GLUT4 (green) in HeLa-GLUT4 cells. Scale 
EDUVȝP*5Hpresentative IF staining for CHC22 (red), calnexin (CNX, blue) and 
GLUT4 (green) in hSkMC-AB1190-GLUT4 6FDOH EDUV  ȝP + 5HSUHVHQWDWLYH
Structured Illumination Microscopy (SIM) of a HeLa-GLUT4 (HeLa-G4) cell (top 
panel) and human skeletal muscle cell (hSkMC-AB1190-GLUT4, bottom panel) 
stained for CHC22 (red) and TGN46 (blue). GLUT4 (green) was detected by GFP tag 
in HeLa-GLUT4 and immunostained with an anti-GFP antibody in hSkMC-AB1190-
GLUT4. Scale bar: ȝP0HUJHGLPDJHVLQ%-H) show red/green overlap in yellow, 
red/blue overlap in magenta, green/blue overlap in cyan, and red/green/blue overlap 
in white. (I) Representative fluorescence intensity plots for GLUT4 (green), CHC22 
(red) and p115, ERGIC-53, GM130 or TGN46 (blue) generated from SIM images of 
the perinuclear region of HeLa-GLUT4 cells. 
 
Figure S2: Surface GLUT4 is recycled to the GSC in proximity to the ERGIC. 
(A) Representative immunofluorescence (IF) staining for internalized surface-labeled 
GLUT4 (HA-tag, blue) and CHC22 (red) for HeLa-GLUT4 cells at 0, 10 or 30 minutes 
after insulin treatment. Total GLUT4 is detected by GFP tag (green). Scale bars: 5 
ȝP % 3HDUVRQ¶V RYHUODS IRU ODEHOLQJ RI &+& DQG +$-tag. Data expressed as 
mean ± SEM, N=3, 8-40 cells per experiment. One-way analysis of variance 
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$129$ IROORZHG E\ %RQIHUURQL¶V PXOWLSOH FRPSDULVRQ SRVW-hoc test *p<0.05, 
****p<0.0001. (C) Representative immunofluorescence (IF) staining for internalized 
surface-labeled GLUT4 (HA-tag, blue) and ERGIC-53 (red) for HeLa-GLUT4 cells at 
0, 10 or 30 minutes after insulin treatment. Total GLUT4 is detected by GFP tag 
JUHHQ6FDOHEDUVȝP'3HDUVRQ¶VRYHUODSIRUODEHOLQJRI(5*,&-53 and HA-
tag. Data expressed as mean ± SEM, N=3, 14-22 cells per experiment. One-way 
DQDO\VLVRIYDULDQFH$129$IROORZHGE\%RQIHUURQL¶VPXOWLSOHFRPSDULVRQSRVW-hoc 
test ****p<0.0001. Merged images show red/green overlap in yellow, red/blue overlap 
in magenta, green/blue overlap in cyan, and red/green/blue overlap in white. 
 
Figure S3: CHC22 re-distributes with p115 following Brefeldin A treatment. 
(A, B) Representative immunofluorescence (IF) staining for CHC22 (blue) and p115 
(red) in HeLa-GLUT4 cells (A) or LHCNM2 myotubes (B) treated or not with Brefeldin 
A (BFA). GLUT4 (green) was detected by GFP tag in HeLa-G4 cells and by IF of 
HQGRJHQRXV SURWHLQ LQ /+&10 FHOOV 6FDOH EDUV  DQG  ȝP IRU $ DQG %
respectively. (C, D) Representative immunofluorescence (IF) staining of HeLa-
GLUT4 cells for CHC22 (blue) and ERGIC-53 (red) in (C) or Rab1 (red) in (D) treated 
or not with BFA and stimulated or not by insulin (Ins). GLUT4 (green) was detected 
E\*)36FDOHEDUVȝP(4XDQWLILFDWLRQRI3HDUVRQ¶VRYHUODSYDOXHVEHWZHHQ
CHC22, GLUT4, ERGIC-53 and Rab1 as in (C & D). Data expressed as mean ± 
SEM, N=3 to 4, 5 to 42 cells per experiment). One-way analysis of variance 
$129$ IROORZHG E\ 7XNH\¶V PXOWLSOH FRPSDULVRQ SRVW-hoc test *p<0.05, 
***p<0.001. (F) Representative immunofluorescence staining for CHC22 (blue), 
ERGIC-53 (red) and GLUT4 (anti-GFP antibody, green) in hSkMC-AB1190-GLUT4 
treated or not with Brefeldin A (BFA) and stimulated or not by insulin (Ins). Scale bar: 
 ȝP Merged images show red/green overlap in yellow, red/blue overlap in 
magenta, green/blue overlap in cyan, and red/green/blue overlap in white. 
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Figure S4: GLUT4 pathway markers are variably recruited to Legionella 
pneumophila¶VUHSOLFDWLYHYDFXROH 
(A) Representative immunofluorescence images of single A549 cells from cultures 
treated with siRNA targeting CHC22 or with non-targeting control siRNA and labeled 
for Sec22b (red) and CHC22 (green), 1h post-infection with wild-type L.p. (MOI=50). 
Arrows point to L.p. detected with DAPI. Boxed inserts show L.p. region at 5X and 2X 
PDJQLILFDWLRQ IRU VL&RQWURO DQGVL&+& UHVSHFWLYHO\6FDOHEDUȝP UHIHUULQJ WR
main images. (B) Quantification of the proportion of L.p. vacuoles staining positive for 
Sec22b. Data expressed as mean ± SEM, N=4, 10 to 20 vacuoles counted per 
experiment as represented in (A). Two-WDLOHG XQSDLUHG 6WXGHQW¶V W-test with equal 
variances ***p<0.001. (C) Representative images of HeLa cells transiently 
expressing FcJRII (needed for L.p. infection) (Arasaki and Roy, 2010), infected with 
wild type (WT) or mutant ǼdotA L.p. (MOI=50, red) and labeled 1 hour post-infection 
with antibodies against Rab1 (green). Hoechst stains the nuclei (blue). Arrows point 
to L.p. 6FDOH EDU  ȝP ' 5HSUHVHQWDWLYH LPDJHV RI $ FHOOV WUDQVLHQWO\
transfected with HA-GLUT4-GFP (green), infected with wild type L.p. expressing 
mono-DsRed protein (L.p.-DsRed, MOI=50, red) and labeled 1 hour post-infection 
with antibodies against endogenous CHC17 (upper panel) or CHC22 (lower panel) 
EOXH 6FDOH EDUV  ȝP ( Representative images of HeLa cells transiently 
expressing FcJRII, infected with wild type (WT) or mutant ǼdotA L.p. (MOI=50, red) 
and labeled 1 hour post-infection with antibodies against Sec16a (E) (green). 
Hoechst stains the nuclei (blue). Arrows point to L.p. 6FDOH EDU  ȝP )
Quantification of the proportion of vacuoles staining positive for Sec16a. Data 
expressed as mean ± SEM, N=3, 50 vacuoles counted per experiment as 
represented in (E). Merged images in (A and D) show red/green overlap in yellow, 
red/blue overlap in magenta, green/blue overlap in cyan, and red/green/blue overlap 
in white. Merged images in (C and E) show red/green overlap in yellow. 
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Figure S5: GM130 depletion affects the secretion of alkaline phosphatase in 
HeLa cells. 
Quantification of alkaline phosphatase secretion index for HeLa-GLUT4 cells treated 
with siRNA targeting CHC22, CHC17, p115 or GM130 or with non-targeting control 
siRNA. The alkaline phosphatase secretion index is the ratio of secreted enzyme 
activity (culture medium) to total cellular activity (secreted plus cell lysate). Data 
expressed as mean ± SEM, N=13-19 independent samples across 2 independent 
assays. One-ZD\ DQDO\VLV RI YDULDQFH $129$ IROORZHG E\ %RQIHUURQL¶V PXOWLSOH
comparison post-hoc test **p<0.01 versus siControl. 
 
Video 1: Live cell imaging of GLUT1 and GLUT4 after simultaneous release 
from the endoplasmic reticulum-example 1. 
HeLa cells expressing the endoplasmic reticulum (ER) Ii-hook fused to streptavidin 
were transfected with HA-GLUT1-SBP-mCherry (GLUT1, red) and HA-GLUT4-SBP-
GFP (GLUT4, green). The intracellular traffic of GLUT1-mCherry and GLUT4-GFP 
was simultaneously tracked in a single cell for 1h after biotin addition concurrently 
released them from the ER. Upon ER exit, both GLUT1 and GLUT4 accumulated in 
the perinuclear region of the cell (yellow), then highly mobile GLUT1 vesicles (red) 
become visible towards the cell periphery while GLUT4 remains perinuclear. The 
time-lapse video was acquired on a spinning disk microscope at 8 frames per 
second. Stills from this video are shown in Fig. 2A. Scale bar: 10 µm. 
 
Video 2: Live cell imaging of GLUT1 and GLUT4 after simultaneous release 
from the endoplasmic reticulum-example 2. 
Time-lapse video microscopy of GLUT1-mCherry and GLUT4-GFP in a single HeLa 
cell for 1 h after simultaneous release from the endoplasmic reticulum, as in Video 1. 
Scale bar: 10 µm. 
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